8 months ago
New Method Targets Drug-Resistant Cancer Mutations
Scientists have found a clever way to fight cancer when medicines stop working.
Normally, cancer cells change over time and become resistant to drugs.
But these researchers discovered that the very changes making the cancer resistant can actually be used to attack the cancer.
They created a computer tool called SpotNeoMet that finds these common changes in many patients.
These changes produce tiny protein pieces called neo-antigens that only appear on cancer cells.
The idea is to teach the body's immune system to recognize and attack these neo-antigens.
This approach could help many patients because it targets changes shared by different people, unlike personalized treatments that are made for just one person.
The researchers tested this method on a type of prostate cancer and saw good results in lab tests and with mice.
This discovery could change how we treat cancers that don't respond to regular treatments.
Researchers discovered a method to fight treatment-resistant cancers by targeting mutations that cause drug resistance.
A computational tool called SpotNeoMet identifies common therapy-resistant mutations producing neo-antigens.
Neo-antigens are tiny protein fragments appearing only on cancer cells, potentially enabling targeted immunotherapy.
The approach was tested on metastatic prostate cancer, showing promising results in lab experiments and mouse models.
This method differs from personalized therapies as it targets mutations shared by many patients, allowing broader treatment application.
- Who
- International team of researchers led by Weizmann Institute of Science
- What
- Discovered a new method to fight treatment-resistant cancers by targeting drug-resistant mutations
- Where
- Weizmann Institute of Science, Israel, with international collaboration
- When
- Not specified (recent, as per the study publication)
- Why
- To address the challenge of cancer cells becoming resistant to treatments over time
Key facts
- Research Team
- Weizmann Institute of Science (Israel) and international collaborators
- Key Discovery
- Mutations causing drug resistance can be used to fight cancer
- Computational Tool
- SpotNeoMet
- Targeted Proteins
- Neo-antigens (tiny protein fragments)
- Tested Cancer Type
- Metastatic prostate cancer
- Research Outcome
- Promising results in lab experiments and mouse models
- Publication Journal
- Cancer Discovery
Quotes
Prof. Yardena Samuels
Professor at the Weizmann Institute of Science
“Our research demonstrates a broad principle that may change the way we think about treatment-resistant cancer. The same mutations that allow a tumour to evade a drug can, through precise immunotherapy, become the cancer's weak point. Unlike 'boutique' immunotherapies that must be tailored to each individual patient, these therapies could be suitable for large groups of patients.”
assamtribune.com
